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Abstract
Novel action beta-blockers combine many different pharmacological effects. The espindolol exhibits effects through β and
central 5-HT1α receptors to demonstrate pro-anabolic, anti-catabolic, and appetite-stimulating actions. In the ACT-ONE trial,
espindolol reversed weight loss and improved handgrip strength in patients with cachexia due to non-small cell lung cancer or
colorectal cancer. With this trial, another frontier of cachexia management is in sight. Nonetheless, more efficacy and safety
data is needed before new therapeutic indications for novel action beta-blockers can be endorsed.
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It was in 1965 when John Black reported on propranolol
properties.1 This was the start of beta-blockers that have
made it to a standard of care for many clinical conditions,
primarily of cardiovascular origin. The way, however, was
not an easy stroll as many challenges needed to be met.
The heart failure serves as a good example: beta-blockers
were initially contraindicated as it was considered that
blocking the actions of activated sympathetic nervous system
would be detrimental for the patients. Yet, chronic over-
activation may be even more harmful, the Swedish
researchers hypothesized. Thus, they have started to investi-
gate this concept2,3 and pursued it into landmark trials that
transformed beta-blockers into a well-established therapy
for heart failure with reduced ejection fraction.4 Although
beta-blockers are rather heterogenous drug group, the
benefit was demonstrated for several agents.4 Moreover,
next to other cardiovascular conditions, patients with non-
cardiac chronic disease might benefit as well. In observational
studies, the signal was extended to conditions like chronic
obstructive pulmonary disease, which initially was considered
as a contraindication to beta-blocker therapy.5,6
Keeping the heart failure as an example of chronic disease,
we can state that the management for a significant propor-
tion of patients is well established.4 However, despite
relevant advances in management of heart failure, many
patients progress into stage of body wasting and cachexia, a
state that actually represents a public health problem.7,8
Herein, it needs to be emphasized that body wasting is
generalized, and it also involves the heart muscle.9,10 From
this point, it is a small but dare step to cross the boundary
with other chronic disease, the malignant conditions in our
case. Some interesting concepts have been proposed, and
likely, there is significant rationale that cancer per se also
induces cardiovascular changes that eventually manifests
clinically as heart failure.11,12 This actually opened an avenue
for new management strategies for cachexia of different
aetiology, including cancer.13–17
The potential role of beta-blockers in preventing and
treating cancer cachexa has emerged during the last decade.
In fact, the major contributory role of the central and periph-
eral nervous systems in the pathogenesis and phenotype of
cancer cachexia has been recognized since long.18 Recently,
Springer et al.19 and Toledo et al.20 demonstrated in different
experimental models of cancer cachexia that the use of
beta-blockers contributes to the prevention of cardiac and
muscle wasting, respectively. Translating this information
into clinical reality, it is important to note that Watkins
et al.21 have recently published a multicentre review of
ED ITOR IAL
© 2016 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of the Society of Sarcopenia, Cachexia and Wasting Disorders
Journal of Cachexia, Sarcopenia and Muscle 2016; 7: 400–402
Published online 5 August 2016 in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/jcsm.12136
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium,
provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
1425 patients with ovarian cancer and demonstrated that the
use of beta-blockers significantly extends either overall or
disease-specific survival. In particular, the use of non-
selective beta-blockers confers the best survival advantage.
Along with these lines, Coats et al. report about the
findings of the ACT-ONE trial that tested espindolol in
patients with non-small cell lung cancer and colorectal cancer
that have developed cachexia.22,23 With this trial, they
actually bring beta-blockers to next frontier. The selection
of an agent to be tested in the trial is not a play of chance.
Pindolol is a well-known beta-blocker,24 but there are several
bits that need to be appreciated in context of the trial.
Primarily, in the ACT-ONE trial, espindolol was tested.
Pindolol exist in a racemic mixture that combines R-pindolol
and S-pindolol, but they differ in pharmacological properties.
In fact, the espindolol (S-pindolol—that has been used in the
trial) has quite unique effects as it combines actions through
β and central 5-HT1α receptors; this cumulatively translates
into a combination of pro-anabolic (β2 stimulating), anti-
catabolic (β1 blocking), and completely unique appetite
stimulating (5-HT1α receptors) actions that carry significant
potential for wasting conditions like cancer cachexia
(Figure 1). Effectively, Coats et al. have combined existing
pathophysiological facts of (cancer) cachexia with pharmaco-
dynamics profile of espindolol that has translated into
clinically meaningful patient-related outcomes.23,25 The
observed benefits in terms of reversed weight loss as
manifested through maintained fat mass and an increase in
fat free mass, with a simultaneous improvement in handgrip
strength, are viable patient-related outcomes that withstand
scrutiny of clinical relevance.25 In this context, it should be
emphasized that handgrip strength testing was done in a
much more elaborative way than previously. Investigators
by far exceeded the standards of most previous trials that
usually test dominant hand only; the ACT-ONE investigators,
however, took much more comprehensive approach as
they have tested both hands three times and then measured
the handgrip strength of a stronger hand in the fourth
run. Whether this is going to be adopted as a new standard in
clinical trials remains open, yet it certainly is a more natural
and likely less biased way of assessment. It may also be that this
is the reason why ACT-ONE demonstrated an improvement in
the handgrip strength while other trials have failed.
The current study by Coats et al.22 is, amongst other
issues, crucial due to transdisciplinary impact. The field of
cardio-oncology has already entered the clinical arena, but
implications remain rather limited to cardiovascular damage
of cancer therapy and protective effects of heart failure
agents.26 With their approach out of the box, Coats et al.22
showed us how chronic disease management should combine
available knowledge over many disciplines. Novel action
beta-blockers, the espindolol in this case, is aiming for a
new frontier. Initial findings are encouraging, but before
therapy is embraced, more efficacy and safety data is
needed. One of the aspects that deserve attention is drug
dosing and pharmacokinetics. Body wasting and cachexia
modulate not only chemotherapy regimens but have the
potential to influence drug metabolism in general.27–29
Whether the longer survival under beta-blocker therapy is
related to improved nutritional status remains to be assessed.
Figure 1 Espindolol pharmacological actions and implications in cachexia.
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Nevertheless, the results of the ACT-ONE trial strengthen the
link between the neural system and the systemic manifesta-
tions of cancer cachexia and suggest that beta-blocker may
contribute to its prevention and treatment. With initial evi-
dence at hand, it should be easier to conduct more studies,
potentially in cachexia of various aetiologies or at least in sev-
eral forms of cancer. Combining patient, clinical, scientific, and
regulatory perspectives, high-quality data is expected to accu-
mulate and address open issues. Through pharmacodynamic
profile and history of persistence in other fields, novel action
beta-blockers are strong contender to break another para-
digm and to conquer new frontier.
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